• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » CardioNet hits a lifetime low as DOJ probes allegations of false Medicare claims

CardioNet hits a lifetime low as DOJ probes allegations of false Medicare claims

September 14, 2011 By MassDevice staff

CardioNet

Shares of CardioNet Inc. (NSDQ:BEAT) hit a new lifetime low of $3.01 per share on news that the company is undergoing a U.S. Dept. of Justice probe on allegations of making false Medicare claims.

The Pennsylvania-based company revealed that it received a civil investigative demand from the DOJ, prior to which it had no knowledge of a pending investigation, according to the SEC filing.

Shares dropped hard and fast for the cardiac rhythm device maker, hitting a lifetime low of $3.01 on August 31, an 18 percent drop from the prior day’s close at $3.67, making it the biggest loser on the Nasdaq that day, according to Reuters. The stock inched up to $3.16 last week, but sank back down to $3.03 yesterday, where it continued to languish in afternoon trading today.

While the probe came as a surprise, analysts seemed confident that the company will come out relatively clean since it audited its reimbursement systems recently.

"Over the last couple of years, the company went through a major reduction in reimbursement for their services and in that process they had an audit which I think would have highlighted any major issues here," Roth Capital analyst Matt Dolan told the wire service, suggesting that the company begin finding capital to pay off the financial settlement that is a likely result.

Meanwhile, the company lost a bid to dismiss a class action shareholder lawsuit alleging that CardioNet misrepresented its reimbursement status as it prepared for its initial public offering.

A California Superior Court judge denied CardioNet’s request for a demurrer in the shareholder case, the California state equivalent of a dismissal, Law360.com reported (paid).

Judge Joan Lewis concluded that the challengers had "sufficiently pled a material misrepresentation or omission in the registration settlements."

The new lawsuit shares earlier complaints that CardioNet, then-president and CEO Randy Thurman and CFO Martin Galvan mislead investors about Medicare reimbursement and issued too-aggressive earnings forecasts that sent the company’s stock soaring to artificially high levels.

The prior case was dismissed by a Pennsylvania judge in August 2010.

CardioNet reported that it plans to participate fully in the DOJ’s investigation. Company officials did not immediately respond to requests for comment.

Filed Under: Legal News, Medicare, News Well, Wall Street Beat Tagged With: Cardiac Rhythm Management, CardioNet Inc., U.S. Justice Dept. (DOJ)

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy